Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting

BACKGROUND: Current strategies for risk stratification of patients with acute myeloid leukemia assign approximately 40% of patients to the intermediate-risk group, where uncertainty about optimal therapy still persists. OBJECTIVE: The objective of this study was to assess the cost effectiveness of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Gabriel, Rousseau, Ben, Marquis, Miriam, Beaubois, Cyrielle, Sauvageau, Guy, Hébert, Josée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885508/
https://www.ncbi.nlm.nih.gov/pubmed/31392669
http://dx.doi.org/10.1007/s40258-019-00503-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885508/
https://www.ncbi.nlm.nih.gov/pubmed/31392669
http://dx.doi.org/10.1007/s40258-019-00503-5

Ejemplares similares